Prevalence variations in psychotropic treatment of children

Journal of Child and Adolescent Psychopharmacology

Volumn 8, Issue 2, 1998, Pages 99-105

  Zito, Julie Magno ^a   Safer, Daniel J ^b   Riddle, Mark A ^b   Johnson, Richard E ^c   Speedie, Stuart M ^d   Fox, Michael ^e  

^a UNIVERSITY OF MARYLAND   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c CENTER FOR HEALTH RESEARCH   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESIPRAMINE; IMIPRAMINE; METHYLPHENIDATE; PSYCHOTROPIC AGENT;

ADOLESCENT; ADULT; AGE; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CHILD PSYCHIATRY; CONTROLLED STUDY; DEPRESSION; DRUG UTILIZATION; FEMALE; HEALTH MAINTENANCE ORGANIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICAL DECISION MAKING; MENTAL DISEASE; PRESCRIPTION; SEX DIFFERENCE;

EID: 0031755131     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.1998.8.99     Document Type: Article

References (18)

1. AACAP Work Group on Quality Issues: Practice parameters for the assessment and treatment of Attention-Deficit Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry 30:1-111, 1991
2. Biederman J, Trusted R, Greenhill L, Ryan N: Estimation of the association between desipramine and the risk for sudden death in 5- to 14-year-old children. J Clin Psychiatry 56:87-93, 1995
3. Committee on Children with Disabilities: Medication for children with attentional disorders. Pediatrics 98:301-304, 1996
4. Goleman D: Use of antidepressant in children at issue. New York Times, December 15, 1993
5. Hancock L: Mother's little helper. Newsweek 51-56, 1996
6. Jensen PS, Hoagwood K, Petti T: Outcomes of mental health care for children and adolescents: II. Literature review and application of a comprehensive model [Review]. J Am Acad Child Adolesc Psychiatry 35:1064-1077, 1996
7. Jensen PS, Vitiello B, Leonard H, Laughren TP: Child and adolescent psychopharmacology: Expanding the research base. Psychopharmacol Bull 30:3-8, 1994
8. McGee R, Feehan M, Williams S, Partridge F, Silva PA, Kelly J: DSM-III disorders in a large sample of adolescents. J Am Acad Child Adolesc Psychiatry 29:611-619, 1990
9. Rappley MD, Gardiner JR, Jetton RCH: The use of methylphenidate in Michigan. Arch Pediatr Adolesc Med 149:675-679, 1995
10. Safer DJ: Patterns of psychotropic medication prescribed by child psychiatrists in the 1990s. Annual Meeting of the American Academy of Child Adolescent Psychiatry, October 28, 1994 (abstract)
11. Safer DJ, Krager JM: Effect of a media blitz and a threatened lawsuit on stimulant treatment. JAMA 268:1004-1007, 1992
12. Safer DJ, Zito JM, Fine EM: Increased methylphenidate usage for attention deficit disorder in the 1990's. Pediatrics 98:1084-1088, 1996
13. Strom BL: Pharmacoepidemiology. New York, John Wiley and Sons, 1994
14. Vitiello B, Conrad T, Burkhard G, Jensen PS: Survey of the use of psychotropic medication in children and adolescents. Presented at the 19th Collegium Internationale Neuropharmacology, June 27-July 1, 1994, Washington, DC
15. Vitiello B, Jensen PS: Psychopharmacology in children and adolescents: current problems, future prospects: summary notes on the 1995 NIMH-FDA Conference. J Child Adolesc Psychopharmacol 5:5-7, 1995
16. Wolraich ML, Lindgren S, Stromquist A, Milich R, Davis C, Watson D: Stimulant medication use by primary care physicians in the treatment of attention deficit hyperactivity disorder. Pediatrics 86:95-101, 1990
17. Zito JM, Riddle MA: Psychiatric pharmacoepidemiology for children. Child Adolesc Psychiat Clin North Am 4:77-95, 1995
18. Zito JM, Safer DJ, dosReis S, Magder LS, Riddle MA: Methylphenidate patterns among Medicaid youths. Psychopharmacol Bull 33:143-147, 1997